Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
2013 Pipeline Report calls on leaders to get the best HIV, hepatitis C virus (HCV), and tuberculosis drugs, diagnostics, and vaccines to the most people as quickly as possible

HIV i-Base and Treatment Action Group (TAG) called on global and national leaders, research sponsors, and regulatory authorities to work together to make the best HIV, HCV, and TB drugs, diagnostics, and vaccines accessible as fast as possible, according to a report released today at the 7th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.

Published
30 June 2013
From
Treatment Action Group
The beginning of the end of hepatitis C?

A convenient and tolerable cure for nearly all hepatitis C infections may be here by the end of this decade, as new drugs appear at

Published
25 June 2013
From
HIV treatment update
AbbVie Says It Can Be First With New Hepatitis C Drugs

AbbVie Inc. (ABBV) said it can win the race against Gilead Sciences Inc. (GILD) to bring to market a new generation of all-oral hepatitis C drugs.

Published
14 June 2013
From
Bloomberg
FDA Grants Priority Review To Oral Hepatitis C Drug Sofosbuvir, Approval Set For December

Gilead's drug will be the first to hit the market in a new generation of targeted hepatitis C treatments with high cure rates.

Published
10 June 2013
From
Medical Daily
Drugs Go From Hit to Dud in Two Years in Hepatitis Race

The pace of innovation, spurred by drugmakers jostling for a slice of a market that may reach $15 billion by 2018, has turned hepatitis C research into one of the fastest-developing areas of medicine. That boosted Gilead’s shares to a record last month, and left others like Vertex facing dwindling sales as their products quickly go from revolutionary to outdated.

Published
04 June 2013
From
Bloomberg
An all-oral combination phase II study of Simeprevir and Samatasvir (IDX719) for the treatment of hepatitis C virus infection initiated

Medivir today announced that Idenix Pharmaceuticals Inc. has initiated a phase II clinical trial, called HELIX-1, evaluating an all-oral, direct-acting antiviral (DAA) HCV combination regimen of simeprevir, a once-daily protease inhibitor jointly developed by Medivir and Janssen R&D Ireland, and samatasvir (IDX719), Idenix’s once-daily pan-genotypic NS5A inhibitor.

Published
30 May 2013
From
Medivir
Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients

Janssen presented SVR12 results from the phase III PROMISE study of simeprevir in treatment-experienced genotype 1 chronic hepatitis C adult patients with compensated liver disease, including all stages of liver fibrosis, when administered once daily with pegylated interferon and ribavirin.

Published
22 May 2013
From
Janssen press release
Recent Advances in the Treatment of Chronic Hepatitis C Threaten to Leave Some Parts of the World Behind

A scenario may develop where hepatitis C is largely eradicated from the developing world but exits in large pockets in developing countries.

Published
21 May 2013
From
Medscape (requires registration)
U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C

The U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for simeprevir (TMC435), an investigational NS3/4A protease inhibitor administered as a 150 mg capsule once daily with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease.

Published
13 May 2013
From
Janssen press release
New HCV combinations could have a big role in prevention, but only if treatment rates increase

New combinations of hepatitis C drugs could have major public health benefits, a modelling study published in the online edition of Hepatology shows. Scaling-up treatment rates in

Published
11 May 2013
By
Michael Carter

Filter by country